Synthesis and HIV-1 inhibitory properties of new tetrahydrobenzoquinazolinedione and tetrahydrobenzocycloheptenuracil derivatives and of their thioxo analogues

1,6-Bis[(benzyloxy)methyl]uracil derivatives-Novel antivirals with activity against HIV-1 and influenza H1N1 virus

A series of 1,6-bis[(benzyloxy)methyl]uracil derivatives combining structural features of both diphenyl ether and pyridone types of NNRTIs were synthesized. Target compounds were found to inhibit HIV-1 reverse transcriptase at micro- and submicromolar levels of concentrations and exhibited anti-HIV-1 activity in MT-4 cell culture, demonstrating resistance profile similar to first generation NNRTIs. The synthesized compounds also showed profound activity against influenza virus (H1N1) in MDCK cell culture without detectable cytotoxicity. The lead compound of this assay appeared to exceed rimantadine, amantadine, ribavirin and oseltamivir carboxylate in activity. The mechanism of action of 1,6-bis[(benzyloxy)methyl]uracils against influenza virus is currently under investigation.

Synthetic routes to benzosuberone-based fused- and spiro-heterocyclic ring systems

Benzosuberones are an important class of medicinal and pharmaceutical compounds and have recently attracted considerable attention. The present review highlights the progress in the synthesis of benzosuberones and their fused and spiro ring systems up to 2015.

The design and synthesis of 9-phenylcyclohepta[d]pyrimidine-2,4-dione derivatives as potent non-nucleoside inhibitors of HIV reverse transcriptase

Novel compounds, which can be considered as conformationally restricted analogues of MKC-442, have been synthesized and tested as inhibitors of the reverse transcriptase of human immunodeficiency virus type-1 (HIV-1). Reaction of urea with a beta-ketoester furnished 6,7,8,9-tetrahydro-9-phenyl-1H-cyclohepta[d]pyrimidine-2,4-(3H,5H)-dione (6a) and 6,7,8,9-tetrahydro-9-p-tolyl-1H-cyclohepta[d]pyrimidine-2,4-(3H,5H)-dione (6b) which were then alkylated at the N-1 position with chloromethyl ether, allyl bromide and benzyl bromide to afford the target compounds 7a-b, 8a-b, 9 and 10, respectively. The seven-membered, annelated compounds have a relatively rigid structures and can lock the orientation of the aromatic ring. Chemical modification at N-1 of the pyrinidine ring and the 9-phenyl ring was attempted, with the aim of improving the antiretroviral activity. In particular, replacement of the aliphatic group with the phenyl moiety at the terminus of N-1 side chain can enhance the activity. The most active compounds showed activity in the low micromolar range with IC50 values comparable to that of nevirapine. The biological activity results are in accordance with the docking results.

Synthesis of novel acyclonucleosides analogs of pyridothienopyrimidine as antiviral agents

Nucleoside analogs of pyridothienopyramidines were prepared by condensing the sodium salt 2a,b with an acyclic side chain in the form of acetylated haloalkoxyalcohol, and subsequent removal of the protecting acetyl group in ammonia/methanol afforded 4a,b. The O-tosyl derivative of 4a could then be modified to azido- and amino derivatives. Reaction of the sodium salt of 2b with halo-ether, benzyl halo-ether and/or halo-thioether gave N- and S-alkylated products, 8 and 9, respectively. Coupling of 10 with the sodium salt of 2a,b gave the corresponding dioxolane derivatives 11, 13, and 14, which were treated with 80% acetic acid at room temperature to give diols 12, 15, and 16. Treatment of 16 with tosyl chloride afforded the ditosylate 17 and this could then be modified to diazido and diamino derivatives. Some of the products were screened for their biological activity.